SCHEMBL16618385

SCHEMBL16618385

ClCc1ccc(Cl)c(Cl)c1.[Zn]

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.58
PNMT P11086 2/20 0.54
TAAR1 Q96RJ0 1/20 0.54
SIGMAR1 Q99720 3/20 0.47
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
IGF1R P08069 1/20 0.45
ALOX15 P16050 1/20 0.45
AHR P35869 1/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 2/20 0.43
MAPK1 P28482 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
FDPS P14324 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42
SLC6A3 Q01959 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29494831 0.97 IDO1 (0.61) IDO1PNMTTAAR1SIGMAR1POLB
SCHEMBL407334 0.97 IDO1 (0.61) IDO1PNMTTAAR1SIGMAR1POLB
Ammonia Solution, Strong SCHEMBL14485188 0.95 IDO1 (0.58) IDO1PNMTTAAR1SIGMAR1POLB
SCHEMBL7415633 0.80 SIGMAR1 (0.46) IDO1PNMTTAAR1SIGMAR1POLB
SCHEMBL11071591 0.78 AHR (0.64) IDO1PNMTTAAR1AHRTP53
SCHEMBL3298586 0.78 IDO1 (0.64) IDO1PNMTTAAR1SIGMAR1POLB
SCHEMBL11637923 0.77 IDO1 (0.39) IDO1PNMTTAAR1SIGMAR1MAPK1
SCHEMBL29220739 0.77 IDO1 (0.39) IDO1PNMTTAAR1SIGMAR1TSHR
SCHEMBL11219362 0.77 PNMT (0.64) IDO1PNMTTAAR1SIGMAR1IGF1R
SCHEMBL1964765 0.77 IDO1 (0.56) IDO1PNMTTAAR1SIGMAR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663508-B2 Biaryl acyl-sulfonamide compounds as sodium channel inhibitors AMGEN INC. (US) 2017-05-30 US disclosed
US-20160214971-A1 Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors One Amgen Center Drive (US) 2016-07-28 US disclosed
WO-2015051043-A1 BIARYL ACYL-SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS AMGEN INC. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214971-A1 Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors SCN1A, SCN1B, SCN5A IDO1 2526/4885PNMT 3259/4885TAAR1 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.